Glioma

335

Pipeline Programs↗

136

Active Trials↗

118

Companies Involved↗

Glioma is a highly competitive landscape with 335 programs across 118 companies. The most active players are Glaxo Dba Glaxosmithkline, Institut de Recherches Internationales Servier, Astellas. 1 therapy is approved with 24 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

90/100

Pipeline Velocity

59/100

Mech. Concentration

6/100

Completion Rate

70/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Glaxo Dba Glaxosmithkline

3 programs

Institut de Recherches Internationales Servier

2 programs

Astellas

2 programs

Regeneron

1 program

Tetragon Biosciences Ltd

1 program

Candel Therapeutics, Inc.

1 program

Pipeline

Programs by Phase

Preclinical31

Tovorafenib

Day One Biopharmaceuticals

Procarbazine Hydrochloride

Radiation Therapy Oncology Group

Midazolam

Conrado Roberto Hoffmann Filho

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis

Phase 1156

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Atezolizumab

Roche

Abemaciclib

Eli Lilly

Paclitaxel

Teva

Phase 2123

Olaparib

AstraZeneca

PD-1

Sichuan Baili Pharmaceutical Co., Ltd.

Bevacizumab

Bio-Thera Solutions

Thalidomide

Bristol-Myers Squibb

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Phase 324

Isotretinoin

Conrado Roberto Hoffmann Filho

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Carboplatin

Avyxa

Etoposide

Avyxa

Carmustine

Melissa K Accordino

Approved1

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Analysis

Modality Breakdown

85%

Small molecule

298 of 352 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 352 classified programs, each share of the total. Modality classified for 99% of 395 pipeline programs.

Analysis

Trial Status

484

clinical trials

Completed209 · 43%

Recruiting76 · 16%

Terminated61 · 13%

Unknown status43 · 9%

Active, not recruiting33 · 7%

Withdrawn26 · 5%

Other36 · 7%

Clinical Trials

Trial Activity

484 trials

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT07110246·96 enrolled

Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

Recruiting·—·Phase 1·NCT06253234·12 enrolled

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Recruiting·KKaty Peters, MD, PhD·Phase 1·NCT05609994·48 enrolled

A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas

Recruiting·GGONGCHU Biotechnology Co., Ltd·Phase 1·NCT06660056·35 enrolled

Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma

Recruiting·ZZhifeng Tian,MD·Phase 2·NCT06801730·38 enrolled

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03896568·36 enrolled

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

Recruiting·HHuashan Hospital·N/A·NCT06043232·360 enrolled

Modified CV Regimen in Optic Pathway Glioma

Recruiting·—·Phase 2·NCT05278715·75 enrolled

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Recruiting·HHutchmed·Phase 1·NCT07025018·52 enrolled

Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas

Recruiting·—·Phase 2·NCT06687681·40 enrolled

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT05580562·450 enrolled

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recruiting·—·Phase 1·NCT04540107·300 enrolled

ABY-029 Glioma Trial

Recruiting·—·Phase 1·NCT07063693·33 enrolled

Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.

Recruiting·BBiogenea Pharmaceuticals Ltd.·Phase 1·NCT07077616·29 enrolled

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT06610682·15 enrolled

Page 1 of 33

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)